Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.

Melanie Davies et al.PubMed ↗Publisher ↗

It reports 2 registered trials together (NCT03552757, NCT03811574). Each of them votes through its own primary report, so the numbers here are shown and do not vote.

What the trial testedrandomised · 1,595 people · 2021

Randomised comparison

Raised body weight & composition

Doesn’t vote: reports several trials together

4.9×3.6× to 6.6×

Bigger than almost all on the map

As reported

OR 4.88, 95% CI 3.58–6.64

One number in the abstract

the abstract, start to end

… of 388 vs 107 [28.5%] of 376; odds ratio 4.88, 95% CI 3.58 to 6.64; …

← favours treatmentfavours comparator →

could be chance

Body weight & composition

OR 4.883.58–6.64

GLP-1 receptor agonistsBody weight & composition

1 / 3

727 papers cite itlatest 60 shown

2021

…

2026

this paperpooled ittrialcites it

4 trials

NCT03552757phase 31,210 enrolled2018 NCT03811574phase 3401 enrolled2019 NCT07462663phase 480 enrolled2027 NCT0587094348 enrolled2023